Clots in the arteries (arterial thrombosis) are the most common cause of stroke (ischaemic stroke) and have been reported in detail for the first time in young adults who received the Oxford-AstraZeneca COVID-19 vaccine in ...
May 25, 2021
0
10
Although older adults are among the most vulnerable to the ravages of COVID-19, new research warns that young patients can develop long-lasting fatigue and concentration problems, even if their COVID-19 infection was mild.
May 25, 2021
0
1
A small case series of patients who received one dose of either the Pfizer-BioNTech or Oxford-AstraZeneca vaccine found that vaccination was not associated with worsening symptoms or quality of life in patients with persisting ...
May 25, 2021
0
0
Since the COVID-19 pandemic emerged, doctors have reported rare but severe cases in infected children of an inflammatory disorder dubbed multisystem inflammatory syndrome (MIS-C).
May 25, 2021
0
3
A study of healthcare workers shows they were three times more likely to become infected during the COVID-19 pandemic compared to the general population. Around one in five of workers who were infected were asymptomatic and ...
May 25, 2021
0
5
A new study by Cardiff University in collaboration with the University of Hertfordshire has revealed the huge "secondary burden" placed on those closest to people living with Long COVID.
May 25, 2021
0
1
Over a year after the novel coronavirus cemented its grip on the world, much of the conversation surrounding the disease remains simple: how many people died and how many survived?
May 25, 2021
0
2
The United States and other countries called Tuesday for a more in-depth investigation into the COVID-19 pandemic's origins, after an international mission to China earlier this year proved inconclusive.
May 25, 2021
0
2
Half of all US adults have now received full COVID-19 vaccines, the White House said Tuesday, marking another huge milestone in the fight against the pandemic.
May 25, 2021
0
3
US biotech firm Moderna said Tuesday that trials had shown its COVID-19 vaccine is "highly effective" in adolescents aged 12-17 and the company would seek regulators' approval in June.
May 25, 2021
0
1
